Lv4
510 积分 2024-03-04 加入
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
19小时前
待确认
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
21小时前
待确认
Esophagogastric Cancer
22小时前
待确认
Combination Immunotherapy of Glioblastoma with Dendritic Cell Cancer Vaccines, Anti-PD-1 and Poly I:C: A Case Report
3个月前
已完结
Intensity of survivin expression linked to features of aggressive relapsed/refractory diffuse large B-cell lymphoma
3个月前
已完结
Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors
3个月前
已完结
PD‐L1 expression predicts efficacy in the phase II SPiReL trial with MVP‐S, pembrolizumab, and low‐dose CPA in R/R DLBCL
3个月前
已完结
Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients
3个月前
已完结
Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial
3个月前
已完结
Antitumor cytotoxic T-cell response induced by a survivin peptide mimic
3个月前
已完结
皖公网安备34019202002308
